Home » Topics » Immuno-oncology, BioWorld Science

Immuno-oncology, BioWorld Science
RSS

Medarex files IND for MDX-070

Jan. 8, 2003

IND filed for EOS-200-4

Jan. 7, 2003

Crucell regains rights to anti-CD46 antibody

Jan. 7, 2003

G17DT granted orphan drug status in Australia for gastric and pancreatic cancers

Jan. 3, 2003

Campath enters phase I/II trial in NHL

Jan. 3, 2003

NeoPharm seeks FDA guidance on IL-13-PE38 trial design and registration plan

Dec. 30, 2002

Siplizumab combined with stem cell transplantation in refractory NHL

Dec. 23, 2002

New data on the combination of unlabeled and I131-labeled tositumomab in NHL

Dec. 23, 2002

Positive interim results for AG-858/Gleevec combination therapy in CML

Dec. 20, 2002

Epratuzumab safe and effective in non-Hodgkin's lymphoma

Dec. 20, 2002

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 24, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 24, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
ADEL wins $1.04B Sanofi deal for tau-targeting Alzheimer’s drug
BioWorld
ADEL Inc. closed a year-end licensing deal worth up to $1.04 billion with Sanofi SA for ADEL-Y01, a specific tau-targeting Alzheimer’s disease drug candidate in a...